Ai Skin Cancer Diagnostic Device Secures €17.5M Funding, Deploys Across Nhs
UK firm Skin Analytics secures €17.5M Series B; deploys AI device DERM at 26 NHS sites. Aims to cut face-to-face consultations up to 95% addressing dermatologist shortages.
DERM safely triages patients with non-cancerous lesions away from cancer pathways, allowing dermatologists to focus on the patients that need them most. Find ...
MDSW that qualifies as a “high-risk” AI system shall be subject to dual CE marking, under the AI Act as well as under the EU MDR or IVDR but the ...
A British health technology company is implementing an AI-driven diagnostic system for skin cancer, seeking to address global dermatologist shortages and accelerating the time required for a diagnosis.
The company, Skin Analytics, has developed a device it has named DERM. It describes DERM as an AI medical device, stating it is the first to receive the EU MDR Class III CE mark, signifying it meets European regulatory standards for independent clinical decision-making in skin cancer assessment. The company reports the tool can autonomously discharge approximately 40% of urgent referrals, theoretically reducing face-to-face consultations by up to 95%.
Skin Analytics has secured €17.5 million in Series B funding, led by Intrepid Growth Partners. It has stated intentions to expand its deployment across Europe, Australia, and the United States. The technology is currently deployed at 26 National Health Service (NHS) sites in the United Kingdom and has been utilized in assessments involving over 150,000 patients. Skin Analytics aims to establish its technology as a global standard for skin cancer triage.
The development occurs within a context of reported worsening dermatologist shortages internationally. Data indicates approximately 30 dermatology specialists per million population across Europe. Skin Analytics states its DERM system has assisted in the detection of over 14,000 cancers and exhibits a 99.8% Negative Predictive Value. The company asserts this level of accuracy is close to that of a dermatologist. The company states that its approach involves regulatory-grade AI for cancer detection infrastructure.
[V3V Ventures] is linked in connection with the additional article details.
DERM safely triages patients with non-cancerous lesions away from cancer pathways, allowing dermatologists to focus on the patients that need them most. Find ...
MDSW that qualifies as a “high-risk” AI system shall be subject to dual CE marking, under the AI Act as well as under the EU MDR or IVDR but the ...
Related Questions